Pfizer (PFE) Announces FDA Acceptance for Priority Review of sBLA for 20vPnC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pfizer (PFE) stock can outperform even in a 'trough COVID' scenario says Goldman Sachs
January 10, 2023 1:43 PM ESTPfizer (NYSE: PFE) management presented at an investor conference yesterday its Chief Executive Albert Bourla said to have reiterated plans for shaping Pfizer post-Covid.
Following the Pfizer presentation, Credit Suisse analyst Trung Huynh told investors in a note that Pfizer focused on the non-Covid side of the business.
"For the non-COVID sales, Dr. Bourla reiterated its 2020-25 mid-term guide of +6% and also first-time longer-term 2025-30 guidance of 6-10%, which comes in ahead of consensus expectations," wrote Huynh, who maintained... More
Morgan Stanley sees a risk to Pfizer's (PFE) EPS guidance
January 6, 2023 10:08 AM ESTIn a note to clients Friday, Morgan Stanley analyst Terence Flynn said the firm sees downside risk to Pfizer's (NYSE: PFE) EPS guidance.
The analyst explained that Pfizer will provide 1st time 2023 guidance in conjunction with fourth-quarter earnings on January 31 and the company previously noted that they plan to... More
